11:02 AM EDT, 06/28/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Friday it increased the dose of [Z]-endoxifen to 80 milligrams daily from 40 mg in its phase 2 study of [Z]-endoxifen combined with Eli Lilly's ( LLY ) abemaciclib in patients with newly diagnosed estrogen receptor positive / human epidermal growth factor receptor 2 negative breast cancer.

The study protocol was updated after a review of safety, efficacy and pharmacokinetic data from the 80 mg pharmacokinetic run-in cohort of the study, according to the company.

The study targets to enroll about 80 menopausal and pre-menopausal breast cancer patients across two cohorts with 40 participants each, the company said.

Price: 1.15, Change: +0.01, Percent Change: +0.88